Fruquintinib

Drug Profile

Fruquintinib

Alternative Names: HMPL-013

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer
  • Phase II Solid tumours
  • Phase I Gastric cancer

Most Recent Events

  • 17 Jan 2017 Hutchinson Medipharma completes the FRESCO phase III trial for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (NCT02314819)
  • 16 Jan 2017 Efficacy, adverse events and pharmacokinetics data from a phase Ib/II trial in Gastric cancer released by Hutchison MediPharma
  • 29 Nov 2016 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer released by Hutchison Medipharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top